Dr Adam Sharps' Team searches for novel therapeutic strategies to prevent the development of treatment resistance and to overcome the progression of cancer.
Dr Adam Sharp is Leader of the Translational Therapeutics Team and Honorary Consultant Medical Oncologist within the Prostate Cancer Targeted Therapies Group and Drug Development Unit at the ICR and The Royal Marsden NHS Foundation Trust.
I am a bioinformatician working in the Cancer Biomarkers and Translational Therapeutics Teams at the Institute of Cancer Research. I work with next generation sequencing data to understand prostate cancer biomarkers in advanced disease. I have a multidisciplinary background in medicinal chemistry and molecular biology, as well as bioinformatics expertise, particularly in transcriptomics, epigenomics, integrative omics and biostatistics.
I am a Prostate Cancer UK postdoctoral travelling fellow working in the Cancer Biomarkers and Translational Therapeutics teams at Institute of Cancer Research. I am currently focused on developing novel therapeutic strategies, as well as discovering vulnerabilities of advanced prostate cancer, to prevent the development of resistance against drugs currently used in clinical practise to tackle this disease.
I am a Higher Scientific Officer working in the Translational Therapeutics Team at the Institute of Cancer Research. I am supporting the team in various projects with the aim to learn more about prostate cancer biology and to develop novel therapeutic strategies to treat patients with advanced disease.
I am a CRUK Clinical Research Training Fellow working in the Translational Therapeutics Team and the Prostate Cancer Targeted Therapies Group at the Institute of Cancer Research and Royal Marsden Hospital. I have an interest in developing novel therapeutic approaches to improve outcomes for men with advanced prostate cancer. My PhD is focused on the pre-clinical development and translation of strategies to target the intrinsic apoptosis pathway.